The Bull Rankings scorecard — our quality-growth score is 78.1 / 100, built from three pillars scored 0–100: Quality 70, Growth 88, Value 77 (valuation is judged against sector peers). At today's price, our reverse-DCF read says the market is implicitly betting on free cash flow shrinking about 3% next year, then recovering toward 4% a year by year ten — a gauge of how much optimism is already in the stock.
The thesis
Boston Scientific sits on a quality‑growth score of 78.1, with Growth at 88 and Quality at 70. The growth pillar is the engine that justifies the current price. Revenue grew 13.5 % YoY in the trailing twelve months, and the company’s free cash flow of $3.6 billion demonstrates that the business can keep feeding itself. The P/E of 16.8 places BS X in the 25th percentile of Healthcare peers, meaning the market is valuing it cheaper than most contemporaries. The PEG of 0.59 signals that the price is already pricing in a growth trajectory that is below the recent revenue pace. In short, the stock is a value play that still offers a solid upside if the company can sustain its growth momentum.
What the business actually is
Boston Scientific operates two main segments: MedSurg and Cardiovascular. In MedSurg, it sells devices for gastrointestinal conditions—resolution clips, biliary stent systems, stents, electrocautery‑enhanced delivery systems, SpyGlass, single‑use scopes, and duodenoscopes—used in endoscopic retrograde cholangiopancreatography procedures. It also offers endoluminal surgery and infection prevention products, plus urological devices. The Cardiovascular segment focuses on devices that treat heart and vascular diseases. The MedSurg line is the growth driver, with its expanding scope of single‑use scopes and advanced stent technologies.
Why it can (or can't) keep compounding
Margins sit at 17.5 %, and ROE is 14.7 %. Those figures show the company is not just selling devices; it is turning sales into solid returns. The Buying back stock signal from our model underscores management’s confidence in the business’s cash‑generating ability. Boston Scientific’s product portfolio—especially the single‑use scopes and biliary stents—creates a high‑switching‑cost environment for competitors. The technology is highly specialized, and the company’s global manufacturing footprint gives it a cost advantage that rivals cannot replicate quickly. These factors combine to create a moat that should allow the firm to compound earnings for the foreseeable future.
The valuation question
The market’s P/E of 16.8 is cheaper than most Healthcare peers, but the reverse‑DCF tells a different story. Today’s price implies free‑cash‑flow growth of about –3 % in year 1, easing to 4 % by year 10. That starting rate is lower than the trailing revenue growth of 13.5 %. The price is already pricing in a slowdown, suggesting that optimism about future growth is priced in. If the company can maintain its 13.5 % revenue pace, the stock would be undervalued relative to its own growth history. Conversely, if revenue growth stalls, the price already reflects that pessimism.
The bear case
The weakest pillar in our quality‑growth score is Quality at 70. While not a red flag, it indicates that the company’s profitability and return metrics are not as stellar as its growth. A decline in profit margin below 17.5 % would erode the cushion that supports the current valuation. Additionally, the reverse‑DCF’s negative first‑year growth assumption means that any further slowdown in free‑cash‑flow would quickly erode the price premium. A significant recall—such as the recent Class I recall for Imager II angiographic catheters—could dent revenue and erode confidence in the product pipeline.
What would change our mind
If revenue growth slipped below the current 13.5 %, margin fell below 17.5 %, or free‑cash‑flow growth turned negative, the thesis would shift from a value‑plus‑growth play to a cautious stance.